View Item 

Show simple item record

Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placeboâ Controlled Trials
dc.contributor.authorNamas, Rajaie
dc.contributor.authorTashkin, Donald P.
dc.contributor.authorFurst, Daniel E.
dc.contributor.authorWilhalme, Holly
dc.contributor.authorTseng, Chi‐hong
dc.contributor.authorRoth, Michael D.
dc.contributor.authorKafaja, Suzanne
dc.contributor.authorVolkmann, Elizabeth
dc.contributor.authorClements, Philip J.
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorElashoff, R.
dc.date.accessioned2018-03-07T18:24:50Z
dc.date.available2019-05-13T14:45:24Zen
dc.date.issued2018-03
dc.identifier.citationNamas, Rajaie; Tashkin, Donald P.; Furst, Daniel E.; Wilhalme, Holly; Tseng, Chi‐hong ; Roth, Michael D.; Kafaja, Suzanne; Volkmann, Elizabeth; Clements, Philip J.; Khanna, Dinesh; Elashoff, R. (2018). "Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placeboâ Controlled Trials." Arthritis Care & Research 70(3): 439-444.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/142490
dc.publisherWiley Periodicals, Inc.
dc.titleEfficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placeboâ Controlled Trials
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142490/1/acr23282.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/142490/2/acr23282_am.pdf
dc.identifier.doi10.1002/acr.23282
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceLe EN, Wigley FM, Shah AA, Boin F, Hummers LK. Longâ term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70: 1104 â 7.
dc.identifier.citedreferenceAmjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, et al. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, doubleâ blind, randomized controlled trials. Arthritis Rheum 2009; 60: 2490 â 8.
dc.identifier.citedreferenceClements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281 â 5.
dc.identifier.citedreferenceKhanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016; 387: 2630 â 40.
dc.identifier.citedreferencePope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351 â 8.
dc.identifier.citedreferenceVan den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24â week randomized doubleâ blind trial, followed by a 24â week observational trial. Br J Rheumatol 1996; 35: 364 â 72.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655 â 66.
dc.identifier.citedreferenceHoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, doubleâ blind, placeboâ controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54: 3962 â 70.
dc.identifier.citedreferenceTashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in sclerodermaâ related interstitial lung disease (SLS II): a randomised controlled, doubleâ blind, parallel group trial. Lancet Respir Med 2016; 4: 708 â 19.
dc.identifier.citedreferenceDomiciano DS, Bonfa E, Borges CT, Kairalla RA, Capelozzi VL, Parra E, et al. A longâ term prospective randomized controlled study of nonâ specific interstitial pneumonia (NSIP) treatment in scleroderma. Clin Rheumatol 2011; 30: 223 â 9.
dc.identifier.citedreferencePakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298 â 304.
dc.identifier.citedreferenceNadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205 â 12.
dc.identifier.citedreferenceNihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis. Rheumatology (Oxford) 2007; 46: 442 â 5.
dc.identifier.citedreferenceTashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1â year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026 â 34.
dc.identifier.citedreferenceKhanna D, Furst DE, Hays RD, Park GS, Wong WK, Seibold JR, et al. Minimally important difference in diffuse systemic sclerosis: results from the Dâ penicillamine study. Ann Rheum Dis 2006; 65: 1325 â 9.
dc.identifier.citedreferenceClements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: highâ dose versus lowâ dose penicillamine trial. Arthritis Rheum 2000; 43: 2445 â 54.
dc.identifier.citedreferenceKhanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007; 9: 151 â 7.
dc.identifier.citedreferenceNagaraja V, Denton CP, Khanna D. Old medications and new targeted therapies in systemic sclerosis. Rheumatology (Oxford) 2015; 54: 1944 â 53.
dc.identifier.citedreferenceDenton CP, Khanna D. Systemic sclerosis. Lancet 2017; 390: 1685 â 99.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr23282.pdf
Size:
137.8KB
Format:
PDF
View/Open
Name:
acr23282_am.pdf
Size:
149.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.